OncoMatch/Head & Neck Cancer (HNSCC)/PD-L1 (CD274)

Head & Neck Cancer (HNSCC)PD-L1 (CD274) Clinical Trials

57 recruiting trials·Updated daily from ClinicalTrials.gov

PD-L1 CPS ≥1 (pembrolizumab monotherapy) and CPS ≥20 (pembrolizumab monotherapy with strongest benefit) are the approved eligibility thresholds for first-line recurrent/metastatic HNSCC per KEYNOTE-048. Pembrolizumab plus chemotherapy is approved regardless of CPS. Trials investigate novel checkpoint combinations, anti-CTLA-4/LAG-3 regimens, and induction IO strategies in locally advanced CPS-stratified HNSCC.

Match trials to my profile Clinician mode →

Top recruiting

Top recruiting PD-L1 (CD274) Head & Neck Cancer (HNSCC) trials

Ranked by phase and US site count.

See all trials matched to your profile →

Phase 3174 US sites

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

National Cancer Institute (NCI)

Phase 2/Phase 351 US sites

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Bicara Therapeutics

Phase 337 US sites

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Merus B.V.

Phase 2/Phase 318 US sites

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

BioNTech SE

Phase 38 US sites

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

Rakuten Medical, Inc.

Phase 3

A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Akeso

Additional trials

More PD-L1 (CD274) Head & Neck Cancer (HNSCC) trials

See all in search →

Phase 2

NCT04671667Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaPhase 2171 US sites NCT04291105Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsPhase 222 US sites NCT07195734Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerPhase 219 US sites NCT06385080A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck CancerPhase 1/Phase 214 US sites NCT05358548ATATcH Alternating Treatment Plans for Advanced CancerPhase 211 US sites NCT06535607Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsPhase 24 US sites NCT05784688Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsPhase 1/Phase 23 US sites NCT05799144pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal CancerPhase 22 US sites NCT05877430Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic CancerPhase 1/Phase 22 US sites NCT06769698A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPhase 22 US sites NCT06636734Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP TrialPhase 22 US sites NCT06239220PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCPhase 22 US sites NCT07465276Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCCPhase 22 US sites NCT05420948A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck CancerPhase 21 US site

10 international trials (no US sites)

NCT04747054Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck CancersPhase 3 NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCPhase 3 NCT07105592A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell CarcinomaPhase 1/Phase 2 NCT04857164Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in ChinaPhase 2 NCT07090317Iparomlimab and Tuvonralimab in HNSCCPhase 2 NCT06869473Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.Phase 2 NCT06016920Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell CarcinomaPhase 1/Phase 2 NCT05069857Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC PatientsPhase 2 NCT06019130Nivolumab in Children and Adults With Nasopharyngeal CarcinomaPhase 2 NCT06839066A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyPhase 2

Other Head & Neck Cancer (HNSCC) biomarkers

Browse other molecular targets with active Head & Neck Cancer (HNSCC) trials.

EGFR PIK3CA

← All Head & Neck Cancer (HNSCC) clinical trials